JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Docking Study of Human Galactokinase Inhibitors
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Journal of the Chosun Natural Science
  • Volume 8, Issue 4,  2015, pp.267-272
  • Publisher : The Research Institute of Chosun Natural Science
  • DOI : 10.13160/ricns.2015.8.4.267
 Title & Authors
Docking Study of Human Galactokinase Inhibitors
Babu, Sathya;
  PDF(new window)
 Abstract
Galactosemia is a potentially lethal disorder caused by the deficiency of the enzyme galactose-1-phosphate uridyltransferase (GALT) within the Leloir pathway. Galactokinase (GALK) is the enzyme in Leloir pathway which converts -D galactose to galactose 1-phosphate. The elevated level of galactose-1-phosphate, the product of GALK plays a major role in Galactosemia. Therefore the inhibition of GALK is a novel therapy for this disorder. Hence in the present study, we performed molecular docking of twenty inhibitors with different activity against galactokinase into the active site of galactokinase enzyme. The binding mode of these inhibitors was obtained using Surflex dock program interfaced in Sybyl-X2.0. The residues such as SER141, TYR109, ARG105, ARG228, TYR106, GLY346, GLY136, ASP86, ASP186 and SER142 found to interact with inhibitors.
 Keywords
Galactokinase;Inhibition;Active Site;Enzyme;
 Language
English
 Cited by
 References
1.
R. Caputto, L. F. Leloir, R. E. Trucco, C. E. Cardini, and A. C. Paladini, "Enzymatic transformations of galactose into glucose derivatives", J. Biol. Chem., Vol. 179, pp. 497-498, 1949.

2.
H. M. Holden, I. Rayment, and J. B. Thoden, "Structure and function of enzymes of the leloir pathway for galactose metabolism", J. Biol. Chem., Vol. 278, 43885-43888, 2003. crossref(new window)

3.
L. F Leloir, "The enzymatic transformation of uridine diphosphate glucose into a galactose derivative", Arch. Biochem. Biophys., Vol. 33, pp. 186-190, 1951. crossref(new window)

4.
M. Tang, K. Wierenga, L. J. Elsas, and K. Lai, "Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors", Chem-Biol Interact., Vol. 188, pp. 376- 385, 2010. crossref(new window)

5.
C. F. Megarity, M. Huang, C. Warnock, and D. J. Timson, "The role of the active site residues in human galactokinase: implications for the mechanisms of GHMP kinases", Bioorg. Chem., Vol. 39, pp. 120-126, 2011. crossref(new window)

6.
K. J. Isselbacher, E. P. Anderson, K. Kurahashi, and H. M. Kalckar, "Congenital galactosemia, a single enzymatic block in galactose metabolism", Science, Vol. 123, pp. 635-636, 1956. crossref(new window)

7.
K. J. Wierenga, K. Lai, P. Buchwald, and M. Tang, "High-throughput screening for human galactokinase inhibitors", J. Biomol. Screen, Vol. 13, pp. 415-423, 2008. crossref(new window)

8.
L. Liu, M. Tang, M. J. Walsh, K. R. Brimacombe, R. Pragani, C. Tanega, J. M. Rohde, H. L. Baker, E. Fernandez, B. Blackman, J. M. Bougie, W. H. Leister, D. S. Auld, M. Shen, K. Lai, and M. B. Boxer, "Structure activity relationships of human galactokinase inhibitors", Bioorg. Med. Chem. Lett., Vol. 25, pp. 721-727, 2015. crossref(new window)

9.
SYBYL Software , Tripos Associates Inc, St. Louis, USA, 2006.

10.
A. N. Jain, "Scoring functions for protein-ligand docking", Curr. Protein Pept Sc., Vol. 7, pp. 407- 420, 2006. crossref(new window)

11.
A. N. Jain, "Scoring non-covalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities", J. Comput. Aid. Mol. Des., Vol. 10, pp. 427-440, 1996. crossref(new window)

12.
M. K. Paul and A. K. Mukhopadhyay, "Tyrosine kinase-role and significance in cancer", Int. J. Med. Sci., Vol. 1, pp. 101-115, 2004.

13.
P. Singh and T. Madhavan, "Histone deactylase inhibitors as novel target for cancer, diabetes, and inflammation", J. Chosun Natural Sci., Vol. 6, pp. 57-63, 2013. crossref(new window)

14.
S. Kulkarni and T. Madhavan, "Application of docking methods: an effective in silico tool for drug design", J. Chosun Natural Sci., Vol. 6, pp. 100-103, 2013. crossref(new window)

15.
B. Sathya and T. Madhavan, "Comparative molecular field analysis of caspase-3 inhibitors", J. Choun Natural Sci., Vol. 7, pp. 166-172, 2014. crossref(new window)

16.
B. Sathya and T. Madhavan, "Comparative molecular similarity indices analysis of caspase-3 inhibitors", J. Chosun Natural Sci., Vol. 7, pp. 227- 233, 2014. crossref(new window)

17.
M. Shalini and T. Madhavan, "Homology modeling of CCR 4: novel therapeutic target and preferential maker for Th2 cells", J. Chosun Natural Sci., Vol. 7, pp. 234-240, 2014. crossref(new window)